Company / Operating Cash Flow
X4 Pharmaceuticals, Inc Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$96.5M
FY2025
5-year range
-$96.5M / -$25.4M
FY2021-FY2025
Trend
-25.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 5 consecutive years, from -$22M in FY2018 to -$97M in FY2025.
Based on SEC 10-K filings.
-$97M in FY2025.
Declined from -$59M to -$97M over the past 3 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- X4 Pharmaceuticals, Inc's operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 25.2% year-over-year.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$96.5M | -25.2% |
| FY2024 | -$77.1M | -31.1% |
| FY2022 | -$58.8M | -22.4% |
| FY2021 | -$48.1M | -89.0% |
| FY2020 | -$25.4M | -17.5% |
| FY2018 | -$21.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026